PKK Library

Your cart is empty.

Welcome to P K Kelkar Library, Online Public Access Catalogue (OPAC)

Normal view MARC view ISBD view

Risk-sharing in the Pharmaceutical Industry : The Case of Out-licensing /

By: Reepmeyer, Gerrit [author.].
Contributor(s): SpringerLink (Online service).
Material type: materialTypeLabelBookSeries: Contributions to Management Science: Publisher: Heidelberg : Physica-Verlag HD, 2006.Description: XIV, 297 p. 70 illus. online resource.Content type: text Media type: computer Carrier type: online resourceISBN: 9783790816686.Subject(s): Business | Leadership | Management | Industrial management | Economics | Management science | Business and Management | Business Strategy/Leadership | Economics, general | Innovation/Technology ManagementDDC classification: 658.4092 Online resources: Click here to access online
Contents:
Key Issues in Managing Pharmaceutical Innovation -- Risk-sharing as New Paradigm in Pharma R&D Collaborations -- Case Studies on Risk-sharing in Pharma R&D Collaborations -- Characteristics of Risk-sharing in Pharma R&D Collaborations -- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations -- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations -- Conclusion.
In: Springer eBooksSummary: The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. In addition, the Noble Prize awarded economic theory of Adverse Selection is applied to analyze the topic theoretically. The gained insights allow identifying the critical parameters of out-licensing collaborations and thereby provide R&D managers with recommendations on how to conclude and manage this type of deals more effectively.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode Item holds
E books E books PK Kelkar Library, IIT Kanpur
Available EBK5762
Total holds: 0

Key Issues in Managing Pharmaceutical Innovation -- Risk-sharing as New Paradigm in Pharma R&D Collaborations -- Case Studies on Risk-sharing in Pharma R&D Collaborations -- Characteristics of Risk-sharing in Pharma R&D Collaborations -- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations -- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations -- Conclusion.

The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. In addition, the Noble Prize awarded economic theory of Adverse Selection is applied to analyze the topic theoretically. The gained insights allow identifying the critical parameters of out-licensing collaborations and thereby provide R&D managers with recommendations on how to conclude and manage this type of deals more effectively.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha